An interventional study of adherence support system based on a vocal assistant in Hypertension, Treatment Adherence and Compliance and Digital Health, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by Istituto Auxologico Italiano — 5 open to participants now, 5 under way, none of them phase 3. Hypertension · Istituto Auxologico Italiano.
Among the 14 studies in Hypertension by Istituto Auxologico Italiano, this one is one of 2 that started in 2024, is one of 3 with no phase, and was the 11th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →5 of the 14 studies in Hypertension by Istituto Auxologico Italiano are open now, in 3 countries. Recruiting first, the newest first:
Istituto Auxologico Italiano · Sites in Italy
Ages 75+
Istituto Auxologico Italiano · Sites in Italy
Ages 18+
Istituto Auxologico Italiano · Sites in Italy
Ages 18+
Istituto Auxologico Italiano · Sites in Argentina, China
Ages 18–80
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 206 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 200 across the 7 interventional studies, 220 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
2 of the studies in Hypertension by Istituto Auxologico Italiano that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309511Istituto Auxologico ItalianoSubendocardial Viability Ratio in Hypertension | 2026-12-31 |
| NCT06868069Istituto Auxologico ItalianoStudy on Blood Pressure Variability and Frailty in the Older People | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Hypertension by Istituto Auxologico Italiano, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Inadequate medication adherence (MA) in chronic conditions, including cardiovascular prevention, represents an important risk factor. The use of new IT technologies in this setting is supposed to be useful to improve patients' adherence, but currently available solutions have significant limitations, including lack of personalization and reliance on expensive ad hoc systems.
This interdisciplinary project aims to verify the hypothesis that in patients on chronic antihypertensive treatment MA can be improved through the implementation of a novel digital health solution for MA monitoring and support, based on inexpensive and user-friendly, commercially available technology (voice assistant), connected with web interface for the physician. The intervention will be personalized based on the creation of Personas, intended as multidisciplinary-based representations of different user types. This approach will be tested in a randomized clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: adherence support system based on a vocal assistant
Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken. Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.
Adherence (plasma essay - 3m)
Percentage of adherent patients based on plasma essay at follow-up visit
Time frame: after 3 months of randomized intervention
adherence (pill count - 3m)
percentage of adherent patients based on pill count adherence (AdhVA) at follow-up visit
Time frame: after 3 months of randomized intervention
adherence (voice assistant - 3m)
percentage of adherent patients based on voice assistant adherence (AdhVA) at follow-up visit
Time frame: after 3 months of randomized intervention
adherence (questionnaire - 3m)
percentage of adherent patients based on MARS-5I (Medication Adherence Report Scale-5 Italian version) at follow-up visit
Time frame: after 3 months of randomized intervention
Adherence (plasma essay - 5m)
percentage of adherent patients based on plasma essay at final visit
Time frame: after 5 months
adherence (pill count - 5m)
percentage of adherent patients based on pill count adherence (AdhVA) at final visit
Time frame: after 5 months
adherence (voice assistant - 5m)
percentage of adherent patients based on voice assistant adherence (AdhVA) at final visit
Time frame: after 5 months
adherence (questionnaire - 5m)
percentage of adherent patients based on MARS-5I at final visit
Time frame: after 5 months
24h Systolic Blood Pressure (3m)
24-hour systolic blood pressure (ABPM) at follow-up visit
Time frame: after 3 months of randomized intervention
24h Systolic Blood Pressure (5m)
24-hour systolic blood pressure (ABPM) at final visit
Time frame: after 5 months
Started Oct 2024 (actual). Primary completion is estimated for Apr 2026, 18 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 18 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →